Allergic rhinitis - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Allergic rhinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Allergic rhinitis: Overview
Allergic rhinitis, or hay fever, is an allergic response to specific allergens. Common symptoms of allergic rhinitis include sneezing, runny nose, coughing, sore or scratchy throat, itchy eyes, watery eyes, dark circles under the eyes, frequent headaches, eczema-type symptoms, hives, and excessive fatigue. Allergic rhinitis is usually a long-standing condition that often goes undetected in the primary-care setting. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis. Treatment of allergic rhinitis is symptomatic and depends on the type of allergen. Management incudes medication like intranasal corticosteroids, antihistamines, decongestants, immunotherapy, eye drops and nasal sprays. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment.
'Allergic rhinitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic rhinitis pipeline landscape is provided which includes the disease overview and Allergic rhinitis treatment guidelines. The assessment part of the report embraces, in depth Allergic rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Allergic rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Allergic rhinitis Emerging Drugs
Further product details are provided in the report..
Allergic rhinitis: Therapeutic Assessment
This segment of the report provides insights about the different Allergic rhinitis drugs segregated based on following parameters that define the scope of the report, such as:
Allergic rhinitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Allergic rhinitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Allergic rhinitis drugs.
Allergic rhinitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Allergic rhinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Allergic rhinitis: Overview
Allergic rhinitis, or hay fever, is an allergic response to specific allergens. Common symptoms of allergic rhinitis include sneezing, runny nose, coughing, sore or scratchy throat, itchy eyes, watery eyes, dark circles under the eyes, frequent headaches, eczema-type symptoms, hives, and excessive fatigue. Allergic rhinitis is usually a long-standing condition that often goes undetected in the primary-care setting. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis. Treatment of allergic rhinitis is symptomatic and depends on the type of allergen. Management incudes medication like intranasal corticosteroids, antihistamines, decongestants, immunotherapy, eye drops and nasal sprays. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment.
'Allergic rhinitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic rhinitis pipeline landscape is provided which includes the disease overview and Allergic rhinitis treatment guidelines. The assessment part of the report embraces, in depth Allergic rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Allergic rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve Allergic rhinitis.
This segment of the Allergic rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Allergic rhinitis Emerging Drugs
- REGN5713-5714-5715: Regeneron Pharmaceuticals
- Injectable MPL allergy vaccine: Allergy Therapeutics
Further product details are provided in the report..
Allergic rhinitis: Therapeutic Assessment
This segment of the report provides insights about the different Allergic rhinitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Allergic rhinitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Allergic rhinitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Allergic rhinitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Allergic rhinitis drugs.
Allergic rhinitis Report Insights
- Allergic rhinitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Allergic rhinitis drugs?
- How many Allergic rhinitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Allergic rhinitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Allergic rhinitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Allergic rhinitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Abdi Ibrahim Pharmaceuticals
- Allergy Therapeutics
- Regeneron Pharmaceuticals
- Laboratorios LETI
- ALK-Abello
- Advagene Biopharma
- CSPC ZhongQi Pharmaceutical Technology
- Array BioPharma
- Immunotek
- AI-201901
- Injectable MPL allergy vaccine
- REGN5713-5714-5715
- House dust mite allergy immunotherapy
- Birch pollen allergy vaccine tablet
- B 244
- AD 17002
- CSPCHA-115
- VTX-1463
- MM09-MG01
- MG 01/T 517
Introduction
Executive Summary
Allergic rhinitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Allergic rhinitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Allergic rhinitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Allergic rhinitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
REGN5713-5714-5715: Regeneron Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II/III)
Comparative Analysis
Injectable MPL allergy vaccine: Allergy Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
B 244: AOBiome
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
MM09-MG01: Immunotek
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Allergic rhinitis Key Companies
Allergic rhinitis Key Products
Allergic rhinitis- Unmet Needs
Allergic rhinitis- Market Drivers and Barriers
Allergic rhinitis- Future Perspectives and Conclusion
Allergic rhinitis Analyst Views
Allergic rhinitis Key Companies
Appendix
Executive Summary
Allergic rhinitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Allergic rhinitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Allergic rhinitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Allergic rhinitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
REGN5713-5714-5715: Regeneron Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II/III)
Comparative Analysis
Injectable MPL allergy vaccine: Allergy Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
B 244: AOBiome
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
MM09-MG01: Immunotek
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Allergic rhinitis Key Companies
Allergic rhinitis Key Products
Allergic rhinitis- Unmet Needs
Allergic rhinitis- Market Drivers and Barriers
Allergic rhinitis- Future Perspectives and Conclusion
Allergic rhinitis Analyst Views
Allergic rhinitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Allergic rhinitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Allergic rhinitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Allergic rhinitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Allergic rhinitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
